Background: The anticancer effects of phytohormones of cytokinin nature are similar to those of medicinal mushrooms, which are able to synthesize cytokinins in large amounts. Aim: To determine the antiproliferative effect of crude extracts and cytokinin fractions from the mycelial biomass of seven fungi species on colon cancer cells in vitro. Materials and Methods: Cytokinin content in mycelial biomass of Ganoderma lucidum, Lentinula edodes, Trametes versicolor, Pleurotus ostreatus, Morchella esculenta, Hericium coralloides, and Fomitopsis officinalis was determined by high performance liquid chromatography mass spectrometry. The antiproliferative effect of the mushroom extracts on the human colon adenocarcinoma Colo 205 cells was assessed by MTT-test. Results: The content of cytokinins (trans-zeatin, zeatin riboside, isopentenyladenosine, isopentenyladenine and zeatin-O-glucoside) was determined in the mycelial biomass of the medicinal macromycetes. Zeatin-type hormones prevailed in all species, though trans-zeatin was the most abundant in H. coralloides and M. esculenta. In P. ostreatus, only zeatin-O-glucoside was detected. The lowest IC50 was found for both the cytokinin fraction (0.21 μg/ml) and the crude extract (0.17 μg/ml) from mycelial biomass of H. coralloides. F. officinalis also demonstrated high antiproliferative effect against Colo 205 cells: IC50 was 0.9 μg/ml for the crude extract and almost twice lower for the cytokinin fraction. In the studied concentration range (0.016–2 μg/ml), the crude extracts from G. lucidum and M. esculenta and the cytokinin fraction from L. edodes did not reach IC50 values. Conclusions: The present study showed that crude extracts and/or cytokinin fractions of several medicinal Basidiomycetes species are capable to inhibit proliferation of colon cancer cells in vitro. Crude extract cytotoxicity of H. coralloides, P. ostreatus and T. versicolor was higher than that of cytokinin fraction while antiproliferative effect of cytokinin fraction from F. officinalis was higher than that in its crude extract.
The Сoronavirus disease 2019 (COVID-19) pandemic has had an extremely serious impact on the livelihoods of people worldwide. Despite the mainly respiratory manifestations of SARS-CoV-2 infection, its consequences can affect the functioning of most systems of organism, including the musculoskeletal, dysfunction of which is a leading factor in disability of the population. Diseases of the joints are one of the most common pathologie of modernity, which in the last decade are increasingly found in young people and even children. The musculoskeletal symptoms can be observed as isolated clinical signs and expressed regardless of the severity of the viral disease. Chronic fatigue, myalgia, swelling and joint pain may occur during the acute phase of COVID-19 and as short-term or long-term complications, but their prevalence has not been systematically studied. Considering the wide range of clinical manifestations of SARS-CoV-2 infection and the complexity of their pathogenesis, the mechanisms underlying lesions of musculoskeletal system and rheumatological complications remain unclear. Today, the main research in this direction is focused mainly on a complete understanding of the regulatory pathways of immune dysregulation and inflammation. Excessive secretion of pro-inflammatory cytokines, disruption of signal transduction and immune response are the result of the severe impact of SARS-CoV-2 infection on most organs, including joints, as well as the use of corticosteroids for the treatment of patients with COVID-19. The presented review highlights generalized information on the main pathophysiological processes that can occur in the joints as a manifestation of the impact of SARS-CoV-2 infection, and possible key mechanisms which contribute to the progression of pathological changes.
According to World Health Organization, antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. Therefore, searching for new antimicrobial agents of natural origin is an extraordinary global problem. The work aimed to determine the antimicrobial activity of lyophilized enzymatic lysate of cells of the Lactobacillus rhamnosus V strain of lactic acid bacteria. The object of the study was the drug Del-Imun V®, which hasanti-allergican dimmuno stimulating activity. The researchers' efforts aimed to fully reveal the drug's potential, particularlyitsanti microbialaction. Antimicrobial activity was determined by the minimum inhibitory concentration (MIC). Determination of MIC was carried out by the method of twotime serial dilutions in meat-peptone broth (MPB) for bacteria and liquid wort for yeast. Gram-negative (Escherichia coli IEM-1, Proteus vulgaris PA-12, Pseudomonas sp. MI-2) and Gram-positive (Bacillus subtilis BТ-2, Staphylococcus aureus BМС-1) bacteria, as well as yeast (Candida albicans D-6, Candida tropicalis PE-2, Candida utilis BVS-65). It was shown that MIC valuesof the native preparation for the bacterial test cultures (EscherichiacoliIEM-1, Bacillussubtilis BT-2, Staphylococcusaureus BMS-1, Proteusvulgaris PA-12, Pseudomonassp. MI-2) were 8 time slower, than those of the thermally in activated preparation, forthe yeasts (Candidaalbicans D-6, Candidatropicalis PE-2, Candidautilis BVS-65) – 4-8 time slower. As a result of the conducted research, the antibacterial and antifungal activity of the drugDel-Imun V® was established. The spectrum of antimicrobial activity concerned gram-positiveand gram-negative bacteria and yeast-like fungi of the genus Candida. The minimum inhibitory concentrations were quite low: from 1.0 to 4.0 μg/ml for bacterial cultures and from 62.5 to 125 μg/ml for yeast. The culture of B. subtilis BT-2 was the least sensitive to the drug's action (MIC – 12.5 μg/ml). There fore, it can be concluded that the lysate of Lactobacillus rhamnosus V lacticacid bacteriahasanti bacteria landanti fungal properties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.